Factor IX Antibody (GMA-138): sc-65952
- Factor IX Antibody (GMA-138) is a mouse monoclonal IgG1, cited in 1 publications, provided at 100 µg/ml
- raised against Factor IX of human origin
- recommended for detection of Factor IX of human origin by WB and IP
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for Factor IX Antibody (GMA-138). This work is in progress.
QUICK LINKS
SEE ALSO...
Factor IX Antibody (GMA-138) is a mouse monoclonal IgG1 antibody that detects coagulation factor IX in human samples through western blotting (WB) and immunoprecipitation (IP) applications. Factor IX, also known as plasma thromboplastic component, plays a crucial role in the blood coagulation cascade, which is essential for hemostasis following tissue injury. This vitamin K-dependent serine protease is synthesized in the liver and circulates as an inactive precursor until activated by factor XIa-mediated proteolytic cleavage, resulting in factor IXa. The active form consists of a 145 amino acid light chain and a 236 amino acid catalytic heavy chain, which are linked by disulfide bonds. Factor IX deficiencies or genetic alterations at the Factor IX locus can lead to hemophilia B, a bleeding disorder that significantly impacts patients′ quality of life. Understanding the structure and activation mechanism of factor IX is important for developing targeted therapies and improving treatment strategies for individuals affected by this condition. Anti-Factor IX antibody (GMA-138) serves as an invaluable tool for researchers studying coagulation pathways and related disorders.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
Factor IX Antibody (GMA-138) References:
- Factor IX mutants with enhanced catalytic activity. | Hartmann, R., et al. 2009. J Thromb Haemost. 7: 1656-62. PMID: 19656280
- Population pharmacokinetic modelling of factor IX activity after administration of recombinant factor IX in patients with haemophilia B. | Suzuki, A., et al. 2016. Haemophilia. 22: e359-66. PMID: 27353956
- Single synonymous mutation in factor IX alters protein properties and underlies haemophilia B. | Simhadri, VL., et al. 2017. J Med Genet. 54: 338-345. PMID: 28007939
- EGF domain of coagulation factor IX is conducive to exposure of phosphatidylserine. | Hidai, C., et al. 2017. Cell Biol Int. 41: 374-383. PMID: 28150893
- Inhibitor development in an elderly patient with severe factor IX deficiency being treated with ALPROLIX, a recombinant factor IX Fc fusion protein. | Comerford, C., et al. 2021. Haemophilia. 27: e484-e486. PMID: 33215798
- Proteolytic inactivation of blood coagulation factor IX by thrombin. | Kisiel, W., et al. 1985. Blood. 66: 1302-8. PMID: 4063523
- Post-natal development of factor IX. | Schettini, F., et al. 1980. Acta Paediatr Scand. 69: 53-8. PMID: 7368912
- Human factor IX corrects the bleeding diathesis of mice with hemophilia B. | Kung, SH., et al. 1998. Blood. 91: 784-90. PMID: 9446637
- Some human inhibitor antibodies interfere with factor VIII binding to factor IX. | Zhong, D., et al. 1998. Blood. 92: 136-42. PMID: 9639509
- Neutrophil elastase cleavage of human factor IX generates an activated factor IX-like product devoid of coagulant function. | Samis, JA., et al. 1998. Blood. 92: 1287-96. PMID: 9694717
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Factor IX Antibody (GMA-138) | sc-65952 | 100 µg/ml | $316.00 |